Background Tumor necrosis factor-α is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α. The purpose of this study was to validat...Background Tumor necrosis factor-α is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α. The purpose of this study was to validate the efficacy and safety of 5 mg/kg infliximab therapy in Chinese patients with moderate to severe plaque psoriasis. Methods In this multicenter, double-blind, placebo-controlled trial, 129 patients with moderate-to-severe psoriasis were randomized to the induction therapy （weeks 0, 2 and 6） with infliximab 5 mg/kg （n=84） or placebo （n=45）, followed with infliximab 5 mg/kg scheduled at week 14 and week 22 in the infliximab group, and infliximab 5 mg/kg scheduled at weeks 10, 12 and 16 in the placebo group. The primary end point was the proportion of patients who achieved at least 75% improvement in Psoriasis Area and Severity Index （PASI 75 response rate） from baseline at week 10. Results At week 10, 81.0% of patients treated with infliximab （5 mg/kg） achieved a 75% or greater improvement compared with 2.2% of patients treated with placebo （P 〈0.001）. A significant improvement in PASI, Physician＇s Global Assessment （PGA） and Dermatology Life Quality Index （DLQI）, was seen from week 6 through week 14 in the infliximab group compared with the placebo group. Through week 22, PASI, PGA, DLQI were well maintained. The incidence of adverse events for the infliximab treatment group was slightly higher in comparison to the placebo treatment group during the first 10 weeks without statistical significance. However, there were 3 cases of tuberculosis that developed during the 26 weeks treatment with infliximal. Conclusions Infliximab treatment was effective as induction and maintenance treatments for Chinese patients with moderate to severe plaque psoriasis. Most drug-induced adverse events were mild to moderate, and well tolerated. Screening for tuberculosis is essential and prophylactic treatment should be given if necessary.展开更多
Background The nevus of Ota, is a common benign pigmentary dermatosis, mainly involve innervation area of first and second branch of trigeminal nerve. The classification of nevus of Ota was proposed by Tanino, based o...Background The nevus of Ota, is a common benign pigmentary dermatosis, mainly involve innervation area of first and second branch of trigeminal nerve. The classification of nevus of Ota was proposed by Tanino, based on 26 cases of nevus of Ota from 1937 to 1940. Studies about its classification are rarely seen in last 70 years, while it is still practical today.展开更多
The coronavirus disease 2019(COVID-19)outbreak affects the use of biologics for psoriatic patients,in the way that the consequential immunosuppression potentially alters a patient’s susceptibility to the virus or det...The coronavirus disease 2019(COVID-19)outbreak affects the use of biologics for psoriatic patients,in the way that the consequential immunosuppression potentially alters a patient’s susceptibility to the virus or deteriorate the condition if the patient is infected or even change the prognosis of infection.Therefore,authors reviewed currently available recommendations from international psoriasis academic organizations and specialists,and summarized them with the specific situation in China.We are trying to provide guidance to the use of biologics for psoriatic patients in the following contexts:patients on biologic therapy,patients being considered for biologic therapy initiation,patients with low-risk or high-risk of SARS-CoV-2 coronavirus infection,patients tested negative or positive for the nucleic acid testing of virus.展开更多
Biologic drugs have been increasingly used in the treatment of psoriasis and are especially favorable for severe,recalcitrant,and special-type cases.Therefore,appropriate,effective,and safe use of biologic drugs has d...Biologic drugs have been increasingly used in the treatment of psoriasis and are especially favorable for severe,recalcitrant,and special-type cases.Therefore,appropriate,effective,and safe use of biologic drugs has drawn attention from dermatologists.For this purpose,Chinese experts majoring in psoriasis analyzed domestic and international research data,summarized current clinical experiences,investigated features of Chinese patients with psoriasis,and finally formulated the present consensus,which provides detailed guidances to clinicians in terms of the principles and methods of the application of biologics,the efficacy and safety profile,patient screening and monitoring,main adverse events and corresponding solutions,and precautions for special patient populations.展开更多
文摘Background Tumor necrosis factor-α is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α. The purpose of this study was to validate the efficacy and safety of 5 mg/kg infliximab therapy in Chinese patients with moderate to severe plaque psoriasis. Methods In this multicenter, double-blind, placebo-controlled trial, 129 patients with moderate-to-severe psoriasis were randomized to the induction therapy （weeks 0, 2 and 6） with infliximab 5 mg/kg （n=84） or placebo （n=45）, followed with infliximab 5 mg/kg scheduled at week 14 and week 22 in the infliximab group, and infliximab 5 mg/kg scheduled at weeks 10, 12 and 16 in the placebo group. The primary end point was the proportion of patients who achieved at least 75% improvement in Psoriasis Area and Severity Index （PASI 75 response rate） from baseline at week 10. Results At week 10, 81.0% of patients treated with infliximab （5 mg/kg） achieved a 75% or greater improvement compared with 2.2% of patients treated with placebo （P 〈0.001）. A significant improvement in PASI, Physician＇s Global Assessment （PGA） and Dermatology Life Quality Index （DLQI）, was seen from week 6 through week 14 in the infliximab group compared with the placebo group. Through week 22, PASI, PGA, DLQI were well maintained. The incidence of adverse events for the infliximab treatment group was slightly higher in comparison to the placebo treatment group during the first 10 weeks without statistical significance. However, there were 3 cases of tuberculosis that developed during the 26 weeks treatment with infliximal. Conclusions Infliximab treatment was effective as induction and maintenance treatments for Chinese patients with moderate to severe plaque psoriasis. Most drug-induced adverse events were mild to moderate, and well tolerated. Screening for tuberculosis is essential and prophylactic treatment should be given if necessary.
文摘Background The nevus of Ota, is a common benign pigmentary dermatosis, mainly involve innervation area of first and second branch of trigeminal nerve. The classification of nevus of Ota was proposed by Tanino, based on 26 cases of nevus of Ota from 1937 to 1940. Studies about its classification are rarely seen in last 70 years, while it is still practical today.
基金HUST COVID-19 Rapid Response Call Program(2020kfyXGYJ056)Hubei Provincial Emergency Science and Technology Program for COVID-19(2020FCA037)
文摘The coronavirus disease 2019(COVID-19)outbreak affects the use of biologics for psoriatic patients,in the way that the consequential immunosuppression potentially alters a patient’s susceptibility to the virus or deteriorate the condition if the patient is infected or even change the prognosis of infection.Therefore,authors reviewed currently available recommendations from international psoriasis academic organizations and specialists,and summarized them with the specific situation in China.We are trying to provide guidance to the use of biologics for psoriatic patients in the following contexts:patients on biologic therapy,patients being considered for biologic therapy initiation,patients with low-risk or high-risk of SARS-CoV-2 coronavirus infection,patients tested negative or positive for the nucleic acid testing of virus.
文摘Biologic drugs have been increasingly used in the treatment of psoriasis and are especially favorable for severe,recalcitrant,and special-type cases.Therefore,appropriate,effective,and safe use of biologic drugs has drawn attention from dermatologists.For this purpose,Chinese experts majoring in psoriasis analyzed domestic and international research data,summarized current clinical experiences,investigated features of Chinese patients with psoriasis,and finally formulated the present consensus,which provides detailed guidances to clinicians in terms of the principles and methods of the application of biologics,the efficacy and safety profile,patient screening and monitoring,main adverse events and corresponding solutions,and precautions for special patient populations.
